Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line nonsmall cell lung cancer successfully concluding regulatory preparations for the trial design Efti in combination with MSD's KEYTRUDA® reports positive efficacy and favourable safety in firstline head and neck cancer in TACTI-003 Phase IIb trial First participant successfully dosed in the first-in-human Phase I trial of IMP761, a novel LAG-3 agonist antibody designed to treat autoimmune diseases Immutep added to ...